The purpose of this study is to investigate the effect of semaglutide in women with Polycystic Ovarian Syndrome(PCOS ) and determine potential therapeutic benefits.

开始日期2025-01-01

申办/合作机构

Methodist Health System, Inc.

NCT05714683 / Not yet recruitingN/A

A Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus® (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea

The aim of this study is to assess the safety and effectiveness of Rybelsus initiated according to label in adults with Type 2 Diabetes Mellitus (T2DM) under routine clinical practice conditions. Participants will get Rybelsus as prescribed by study doctor. The study will last for about 26 weeks.

开始日期2024-12-31

申办/合作机构

Novo Nordisk A/S

NCT06387199 / Not yet recruiting临床2/3期IIT

Alleviating Carbohydrate Counting Using Weekly Subcutaneous Semaglutide Injections in People With Type 1 Diabetes on Closed-Loop Insulin Therapy: a 2x4 Factorial Randomized Placebo-Controlled Trial

A closed-loop insulin system, often labelled the "artificial pancreas" (AP), consists of an insulin pump, a continuous glucose monitor, and an interface coordinating between them to regulate insulin dosage based on glucose levels. Primarily designed for managing type 1 diabetes, this system has demonstrated significant benefits in previous studies. Yet, despite these advantages, certain challenges persist.
Semaglutide, utilized in treating type 2 diabetes and obesity, is a once-weekly injectable medication that elevates levels of a gastrointestinal hormone known as Glucagon-Like Peptide-1 (GLP-1). This hormone alters gastric emptying, inhibits glucagon release, and reduces appetite. While not officially sanctioned for type 1 diabetes treatment in North America, studies have explored its efficacy as an adjunctive therapy alongside insulin, yielding favorable outcomes in blood glucose regulation. Comparable drugs like liraglutide and exenatide have been employed in type 1 diabetes treatment as well, albeit with less pronounced glucose-regulating effects compared to semaglutide, even in type 2 diabetes.
The goal of this 50-week randomized placebo-controlled crossover 2x4 factorial designed trial is to assess whether commercial automated insulin delivery (AID) systems using rapid-acting insulin with adjunct weekly injections of semaglutide (at the maximally tolerated dose) can replace carbohydrate counting with simple meal announcements (SMA) without degrading glucose control.

开始日期2024-07-01

申办/合作机构-

100 项与司美格鲁肽 (诺和诺德) 相关的临床结果

登录后查看更多信息

100 项与司美格鲁肽 (诺和诺德) 相关的转化医学

登录后查看更多信息

100 项与司美格鲁肽 (诺和诺德) 相关的专利（医药）

登录后查看更多信息

694

项与司美格鲁肽 (诺和诺德) 相关的文献（医药）

2024-04-01·The American Journal of Emergency Medicine

GLP-1 agonists: A review for emergency clinicians

Review

作者: Koyfman, Alex ; Pelletier, Jessica ; Long, Brit ; Bridwell, Rachel E

INTRODUCTION:

Glucagon-like peptide 1 (GLP-1) based therapies, including GLP-1 agonists, are currently in use for treatment of diabetes and obesity. However, several complications may occur with their use.

OBJECTIVE:

This narrative review provides a focused evaluation of GLP-1 agonist therapy and associated complications for emergency clinicians.

DISCUSSION:

GLP-1 agonists potentiate insulin release and reduce gastric emptying and food intake. These agents have demonstrated significant improvements in glucose control in diabetics and weight loss in obese patients. The two most common agents include subcutaneous semaglutide (Ozempic, approved for type 2 diabetes, and Wegovy, approved for weight loss) and liraglutide (Saxenda, approved for weight loss, and Victoza, approved for type 2 diabetes), though an oral formulation of semaglutide is available (Rybelsus). While these drugs are associated with improved long-term outcomes, there are a variety of associated adverse events. The most common include gastrointestinal (GI) adverse events such as nausea, vomiting, diarrhea, and abdominal pain. Pancreatitis and biliary disease may also occur. Hypersensitivity including injection site reactions have been associated with use, with reports of anaphylaxis and other rashes. Renal adverse events are most commonly associated with severe GI losses. Hypoglycemia may occur when these agents are used with sulfonylureas or insulin. There is also an increased risk of diabetic retinopathy. Due to the current shortage and expense of these medications, many patients have attempted to obtain these medications from non-licensed and unregulated agents, which may be associated with increased risk of serious complications.

CONCLUSIONS:

An understanding of the indications for GLP-1 agonist use and associated adverse events can assist emergency clinicians.

2024-02-01·Endocrine Connections

GLP-1 and PYY for the treatment of obesity: a pilot study on the use of agonists and antagonists in diet-induced rats

Article

作者: Fassnacht, Martin ; Maack, Christoph ; Nickel, Alexander ; Sequeira, Vasco ; Kloock, Simon ; Ziegler, Christian G ; Dischinger, Ulrich ; Kohlhaas, Michael ; Oertel, Marie

Objective:

Combination therapies with gut hormone analogs represent promising treatment strategies for obesity. This pilot study investigates the therapeutic potential of modulators of the glucagon-like peptide 1 (GLP-1) and neuropeptide Y (NPY) system using GLP-1 receptor agonists (semaglutide) and antagonists (exendin 9-39), as well as non-selective and NPY-Y2-receptor selective peptide tyrosine tyrosine (PYY) analogs (PYY3-36/NNC0165-0020 and NNC0165-1273) and an NPY-Y2 receptor antagonist (JNJ31020028).

Methods:

High-fat diet (HFD)-induced obese rats were randomized into following treatment groups: group 1, nonselective PYY analog + semaglutide (n = 4); group 2, non-selective and NPY-Y2 receptor selective PYY analog + semaglutide (n = 2); group 3, GLP-1 receptor antagonist + NPY-Y2 receptor antagonist (n = 3); group 4, semaglutide (n = 5); and group 5, control (n = 5). Animals had free access to HFD and low-fat diet. Food intake, HFD preference and body weight were measured daily.

Results:

A combinatory treatment with a non-selective PYY analog and semaglutide led to a maximum body weight loss of 14.0 ± 4.9% vs 9.9 ± 1.5% with semaglutide alone. Group 2 showed a maximum weight loss of 20.5 ± 2.4%. While HFD preference was decreased in group 2, a strong increase in HFD preference was detected in group 3.

Conclusions:

PYY analogs (especially NPY-Y2 selective receptor agonists) could represent a promising therapeutic approach for obesity in combination with GLP-1 receptor agonists. Additionally, combined GLP-1 and PYY3-36 receptor agonists might have beneficial effects on food preference.

2024-03-01·Peptides

Recent advances in peptide-based therapies for obesity and type 2 diabetes

Article

作者: Flatt, Peter R ; Conlon, J Michael ; Bailey, Clifford J

Options for the treatment of type 2 diabetes mellitus (T2DM) and obesity have recently been expanded by the results of several large clinical trials with incretin-based peptide therapies. Most of these studies have been conducted with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide, which is available as a once weekly subcutaneous injection and once daily tablet, and the once weekly injected dual agonist tirzepatide, which interacts with receptors for GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). In individuals with T2DM these therapies have achieved reductions of glycated haemoglobin (HbA1c) by > 2% and lowered body weight by > 10%. In some studies, these agents tested in non-diabetic, obese individuals at much higher doses have lowered body weight by > 15%. Emerging evidence suggests these agents can also offer cardio-protective and potentially reno-protective effects. Other incretin-based peptide therapies in early clinical development, notably a triple GLP-1/GIP/glucagon receptor agonist (retatrutide) and a combination of semaglutide with the amylin analogue cagrilintide (CagriSema), have shown strong efficacy. Although incretin therapies can incur adverse gastrointestinal effects these are for most patients mild-to-moderate and transient but result in cessation of treatment in some cases. Thus, the efficacy of new incretin-based peptide therapies is enhancing the opportunity to control body weight and blood glucose and improve the treatment of T2DM and obesity.

2,265

项与司美格鲁肽 (诺和诺德) 相关的新闻（医药）

13 小时之前

·Insight数据库

礼来霸气连开 8 项 III 期临床，三靶点激动剂 Retatrutide 加速进场

4 月 25 日，据 ClinicalTrials.gov 平台显示，礼来 Retatrutide 启动一项新 III 期临床试验，旨在评估每周 1 次 Retatrutide 对成人肥胖患者的心血管结局和肾功能的影响（登记号：NCT06383390）。来自： ClinicalTrials.gov 这些患者体重指数 BMI（体重 / 身高的平方）≥ 27 kg/m^2 且患有动脉粥样硬化性心血管疾病和/或慢性肾脏疾病。目标入组 10000 名受试者，并预计于今年 5 月 1 日完成首例受试者的入组工作。Retatrutide（LY3437943/瑞他鲁肽）是一款 GLP-1R/GCGR/GIPR 三靶点激动剂。II 期临床试验结果显示，在治疗 48 周时，每周注射 12mg Retatrutide 治疗的受试者平均体重可减轻 24.2%。据 Insight 数据库显示，此前已在全球登记启动了 7 项 III 期临床，此次是第 8 项。率先启动的是减重适应症，去年启动了 4 项 TRIUMPH 系列 III 期临床。TRIUMPH-3 针对至少 1 种心血管疾病的严重肥胖患者（BMI ≥35），另外 3 项则探索了超重/肥胖人群膝骨关节炎和阻塞型睡眠呼吸暂停（OSA），而这 3 项试验据此前信息显示均含中国内地地区，不过当前已被移除。Retatrutide 全球已登记的 III 期临床表格数据整理自 Insight 数据库（下同）而在今年又连续启动了 3 项针对降糖适应症的 III 期临床试验。其中，TRANSCEND-T2D-2 试验头对头司美格鲁肽。礼来霸气连开 8 项 III 期临床试验的 Retatrutide，毫无疑问是全球进度最快的 GLP-1R/GCGR/GIPR 三靶点激动剂。不过当前在国内均未启动临床。同靶点产品中，从全球临床进展来看，排在 Retatrutide 之后韩美制药的 efocipegtrutide 已进入 II 期，不过适应症为 MASH。此外，国产企业民为生物布局的 MWN101 同样处于 II 期，不过这是一款抗体类融合蛋白，上个月刚启动了两项分别针对减重和降糖的 II 期临床试验（登记号：CTR20240802、CTR20240817）。封面来源：企业 Logo免责声明：本文仅作信息分享，不代表 Insight 立场和观点，也不作治疗方案推荐和介绍。如有需求，请咨询和联系正规医疗机构。编辑：HebePR 稿对接：微信 insightxb投稿：微信 insightxb；邮箱 insight@dxy.cn多样化功能、可溯源数据……Insight 数据库网页版等你体验点击阅读原文，立刻解锁！

临床3期临床2期临床失败

22 小时之前

·生物谷

GLP-1RA治疗T2DM患者具有明确的心血管获益，与其抗动脉粥样硬化密不可分！

截止至目前为止，糖尿病仍然是全球范围内的重大疾病之一，根据国际糖尿病联盟（IDF）的数据，2019年全球糖尿病患病率估计为9.3%，约有4.63亿人患有糖尿病。截止至目前为止，糖尿病仍然是全球范围内的重大疾病之一，根据国际糖尿病联盟（IDF）的数据，2019年全球糖尿病患病率估计为9.3%，约有4.63亿人患有糖尿病，到2030年，糖尿病的全球预计患病率将增加到10.2%（5.78亿），到2045年将增加到10.9%（7亿）[1]。除了具有发病率高的特点外，糖尿病还是全球范围内死亡和残疾的主要原因，其中心血管并发症占据着重要因素，约占26.8%[2]。在确定排除了传统心血管疾病的危险因素后，包括年龄、肥胖、吸烟、血脂异常和高血压等，糖尿病患者发生心血管不良事件的几率明显高于非糖尿病患者。糖尿病并发的心血管不良事件，不仅给患者的生活质量和生命健康造成了严重威胁，同时也给全球范围内的患者和医疗保健系统带来了巨大的经济负担，具有严重的危害性。因此，全面和深入了解糖尿病的心血管不良事件风险，以确定早期预防和干预的策略，对于保障糖尿病患者生命健康安全具有重要的意义。近年来，由于对糖尿病不良并发症认识的加深和各类新型药物的研发、验证和应用，糖尿病患者的心血管风险呈现出一定的下降趋势。冠心病又称为动脉粥样硬化性心脏病，是心血管不良并发症的主要类型，可表现为稳定性心绞痛、不稳定性心绞痛、心肌梗死和心源性猝死。动脉粥样硬化及其危险因素均促进多种心血管事件的发生，并导致死亡[3]（见表1）。在全球范围内有高达32.2%的2型糖尿病（T2DM）患者可并发冠心病[4]。因此，如何应对动脉粥样硬化性心脏病是近年来糖尿病治疗的重点和热点问题。图1.动脉粥样硬化在心血管事件链中的作用糖尿病相关的心血管不良事件等并发症，给糖尿病的管理策略带来了严峻的挑战，但同时，多项有关评估糖尿病治疗药物的心血管结局试验（CVOT）正在进行或已经完成，为新阶段的糖尿病防治心血管疾病治疗提供了全新的见解和应对方案。肠促胰素，包括胰高血糖素样肽-1（GLP-1）和葡萄糖依赖性胰岛素性多肽（GIP），均属于肠道激素，在营养摄入时分泌，并通过调节胰岛素和胰高血糖素释放来维持血糖控制。GLP-1受体激动剂（GLP-1RA）可通过刺激肠源性肠促胰素的作用或抑制其降解来改善葡萄糖调节，从而起到控制糖尿病患者血糖的作用。此外，根据美国食品和药物管理局的指导意见，新的降糖药物要确保心血管安全性，以应对糖尿病相关的心血管事件并发症的挑战。CVOT研究中主要以心血管死亡、非致死性心肌梗死和非致死性卒中为不良心血管终点（MACE），对GLP-1RA等糖尿病治疗药物的MACE进行了全面的评估。最新的荟萃分析显示，对于合并心脑血管疾病或心脑血管高危因素的T2DM患者，GLP-1RA药物可使其MACE获益，在T2DM患者中，GLP-1RA类药物对心血管病的二级预防与一级预防有效性一致[5]（见图2）。图2. 荟萃分析显示GLP-1RA可使T2DM患者MACE获益 LEADER研究表明，在心血管高危的T2DM患者中，利拉鲁肽较安慰剂显示出显著的心血管获益[6]。来自LEADER研究的另一项分析显示利拉鲁肽还具有降低T2DM合并心血管高危患者的心肌梗死发生率，并可能改善患者心肌梗死的临床结局[7]。CVOT荟萃分析提示，GLP-1RA总体降低MACE风险达14%，其中利拉鲁肽降低MACE风险13%，司美格鲁肽降低MACE风险达26%[8]。大量研究证实GLP-1在人体内具有多重重要的生理作用，GLP-1RA通过激活GLP-1受体以葡萄糖浓度依赖性刺激胰岛素分泌、诱导β细胞增殖及增强对细胞凋亡的抵抗力，还通过直接作用于脂肪组织来促进能量储存，并通过刺激成骨细胞增殖和抑制细胞凋亡来增强骨形成，并可通过调控血压、炎症、血脂异常和微血管功能等动脉粥样硬化的危险因素来达到减少心血管并发症的目的[9]（见表3）。图3.GLP-1改善多种动脉粥样硬化的危险因素动脉粥样硬化的形成和进展是一个复杂的过程，在血管内皮受损的基础上，循环中的低密度脂蛋白（LDL）颗粒从血管腔被运输到血管壁，在细胞外基质中聚积，从而更容易发生氧化，巨噬细胞和平滑肌细胞吞噬脂质后形成泡沫细胞，促进动脉粥样硬化斑块的形成。GLP-1RA可通过减少极低密度脂蛋白、体内泡沫细胞、体内巨噬细胞、内皮功能障碍和氧化应激等多种途径抑制动脉粥样硬化的发生和发展[10]（见图4）。图4.GLP-1RA抑制动脉粥样硬化的多种机制一项动物研究显示，司美格鲁肽和利拉鲁肽等GLP-1RA显著减轻了载脂蛋白E（ApoE）缺陷小鼠和低密度脂蛋白受体缺陷（LDLr）小鼠的斑块病变发展。GLP-1RA可能通过作用于白细胞募集、白细胞滚动、粘附/外渗、胆固醇代谢、脂质介导的信号传导、细胞外基质蛋白转换等多种途径和其抗炎机制来抑制动脉粥样硬化斑块的形成[11]（见图5）。图5.GLP-1RA减少高脂饮食诱导的动脉粥样硬化斑块形成另一项动物研究显示，使用腺病毒载体系统转染ApoE-/-小鼠模型，并给予西方饮食喂养诱导动脉粥样硬化，取小鼠主动脉根部和主动脉弓进行油红染色（Oil-red-O）及天狼猩红染色（PSR）染色观察。结果显示，GLP-1(7-37)、GLP-1(9-37)和GLP-1(28-37)可显著减少小鼠动脉粥样硬化脂质核心并增加纤维帽厚度，达到稳定斑块作用[12]（见图6）。图6.GLP-1RA减少动脉粥样硬化斑块脂质核心及增加纤维帽厚度（稳定斑块）糖尿病相关心血管不良事件仍是糖尿病管理中面临的重大挑战，我们仍需重视心血管并发症的危害。GLP-1RA相关的CVOT试验和其他新进展均证实了包括利拉鲁肽和司美格鲁肽在内的GLP-1RA药物在降糖可靠的基础上，具有显著的抑制动脉粥样硬化进展的作用，并可进一步降低心血管不良事件，这对提高患者生活质量和降低死亡等不良结局均具有十分重要的价值。 [1]Saeedi P , Petersohn I, Salpea P , et al. Global and regional diabetes prev-alence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas. Diabetes Res Clin Pract. 2019;157:107843. [2]Ling W , Huang Y , Huang YM, et al. Global trend of diabetes mortality attributed to vascular complications, 2000–2016. Cardiovasc Diabetol. 2020;19:182 [3]Dzau VJ, Antman EM, Black HR, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation. 2006;114(25):2850-2870. [4] Einarson TR, Acs A, Ludwig C, et al. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol. 2018;17:83. [5]Sattar N et al. Lancet Diabetes Endocrinol. 2021; S2213-8587(21)00203-5. [6]Verma S, Poulter NR, Bhatt DL, et al. Effects of liraglutide oncardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke. Circulation 2018;138:2884–2894 [7]Marso SP, Nauck MA, Monk Fries T, Rasmussen S, Treppendahl MB, Buse JB: Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial). Am J Cardiol. 2018; 121(12):1467-1470. [8]Sattar N, Lee MMY,Kristensen SL,et al.Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.Lancet Diabetes Endocrinol. 2021;9(10):653-662. [9]Dzau VJ, Antman EM, Black HR, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation. 2006;114(25):2850-2870. [10]Rizzo M, Nikolic D, Patti AM, et al. GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms. Biochim Biophys Acta Mol Basis Dis. 2018;1864(9 Pt B):2814-2821. [11]Rakipovski G, Rolin B, Nøhr J, et al. The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE and LDLr Mice by a Mechanism That Includes Inflammatory Pathways. JACC Basic Transl Sci. 2018;3(6):844-857. Published 2018 Nov 21. [12]Burgmaier M, Liberman A, Möllmann J, et al. Glucagon-like peptide-1 (GLP-1) and its split products GLP-1(9-37) and GLP-1(28-37) stabilize atherosclerotic lesions in apoe⁻/⁻ mice. Atherosclerosis. 2013;231(2):427-435. 作者简介：程时武教授解放军第923医院内分泌科主任，副主任医师，医学博士毕业于第四军医大学、解放军301医院广西医师协会内分泌代谢科医师分会副主任委员广西医学会内分泌学分会常委广西医学会糖尿病学分会委员

临床结果申请上市优先审批

2024-04-25

·PRNewswire

Cartessa Aesthetics Unveils PHYSIQ 360, A Revolutionary Non-Invasive Body Contouring Treatment

PHYSIQ 360 offers technological advancements that uniquely meet today's needs within the category MELVILLE, N.Y., April 25, 2024 /PRNewswire/ -- Cartessa Aesthetics, a premier North American aesthetic medical device company, launches PHYSIQ 360, a groundbreaking technology that elevates non-invasive body contouring. PHYSIQ 360 is the next generation of the award-winning PHYSIQ body technology that exemplifies the innovative partnership between Cartessa and DEKA, a leading global aesthetic laser manufacturer. This collaboration has consistently focused on refining established technologies by innovating new methods of energy delivery to enhance performance and results. Building on the versatility and impressive results of PHYSIQ, PHYSIQ 360 provides more customizable and optimized treatments to reduce fat and build muscle in the widest range of skin and body types. Continue Reading NEW PHYSIQ 360 is engineered to offer the most holistic solution that includes fat reduction and muscle stimulation. Post this PHYSIQ 360 body contouring device provides the most holistic solution to reduce fat and stimulate muscle. PHYSIQ 360 is a revolutionary non-invasive body contouring treatment that targets fat and muscle customizable to meet the total body for every body. PHYSIQ 360 is engineered to address the persistent challenges of achieving desired body goals, offering a holistic solution that includes fat reduction through laser energy (LZR) and muscle stimulation (EMS), administered separately or sequentially in a single session via exclusive Sequential Thermal & Electrical Pulse (STEP) technology. PHYSIQ 360's laser energy (LZR) is the first of its kind to incorporate a proprietary PURE BEAM technology, which optimizes laser beam quality and heat delivery to ensure a more uniform fat reduction, proper deep penetration, and a high volume of fat being treated. Cutting edge EMS electrodes deliver strong muscle contractions, with up to four applicators that can be programmed independently to target multiple body areas effectively at once. "DEKA continues to innovate the ways in which non-invasive technologies can shape the body. Our unique partnership with Cartessa ensured that the innovations incorporated into the new PHYSIQ 360 not only met but surpassed the expectations of providers and patients alike", shared Paolo Salvadeo, El.En.'s General Manager and DEKA CEO. PHYSIQ 360 offers fully customizable treatment plans based on a patient's body type and end-goal. With an average recommended treatment plan of five sessions spaced one to two weeks apart, clients can expect a personalized approach that can be adjusted throughout their wellness journey. Unlike traditional methods that may require extensive time commitments and discomfort, PHYSIQ 360 maximizes results while minimizing both treatment time and downtime, ensuring a seamless integration into a patient's regular routine. The surge in popularity of semaglutide and other weight loss medications such as Ozempic, Mounjaro, Wegovy and Zepbound has significantly impacted the body market, including aesthetic providers. Rapid weight loss can lead to side effects like excess skin, uneven fat loss, and muscle depletion. Body contouring treatments can address these downsides, and PHYSIQ 360 stands out as the optimal solution. It also offers an added PLUS lymphatic drainage handpiece to further enhance patient experience. PHYSIQ 360 is complementary to maintain and prolong weight loss results, offering a sustainable approach to total body wellness. "The body shaping and weight-loss category have been forever changed with the proliferation of injectable weight loss medications," commented Gabe Lubin, Cartessa Founder and CEO. "The use of such remedies are becoming more commonplace, and in order to alleviate unwanted side effects and issues with sustained usage, more providers are looking at holistic programs that integrate aesthetic technology. PHYSIQ 360 is the only device that selectively targets fat and sequentially re-educates muscles in one device to address the variable needs along an individual's weight loss journey." About Cartessa Aesthetics, LLC. Cartessa Aesthetics is a leading North American aesthetic company focused on cutting-edge technology and industry leading customer support. Thanks to an independent business model and established relationships with top global manufacturers, Cartessa's product portfolio offers true competitive advantages for practices and patients across every aesthetics category. Customers benefit from expertly vetted devices and end-to-end support to maximize the clinical outcomes and returns of their investment. For more information, visit: . About DEKA M.E.L.A. DEKA M.E.L.A. is a controlled company of the large multinational Italian group EL.EN. The company, which has more than three decades of laser experience, chose DEKA as its company name which means attainment of perfection and excellence and is also "10" in Greek, the perfect number according to Pythagoras. The Florentine company is rooted in a culture that has made excellence of thought its dominant feature. Due to its invaluable cultural heritage and unique historical background, DEKA encompasses into its vision a promise of universal value: to turn every scientific discovery into a concrete benefit for physicians and patients, and to translate every technological innovation into ongoing improvements for the range of products and services it offers. SOURCE Cartessa Aesthetics

100 项与司美格鲁肽 (诺和诺德) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10025	司美格鲁肽 (诺和诺德)	A10BJ06	DB13928

研发状态

适应症	最高研发状态	国家/地区	公司
2型糖尿病	批准上市	美国更多	Novo Nordisk, Inc. 更多
肥胖	批准上市	美国更多	Novo Nordisk, Inc. 更多
阿尔茨海默症	临床3期	英国更多	Novo Nordisk A/S 更多
非酒精性脂肪性肝炎	临床3期	新加坡更多	Novo Nordisk A/S 更多
心脏病	临床3期	中国台湾更多	Novo Nordisk A/S 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04916470 (Literature) 人工标引	临床3期	2型糖尿病 \| 心脏衰竭	616	Semaglutide	蓋製壓襯構壓醖窪鏇醖(顧願夢醖選鑰顧築積憲) = 獵壓醖鑰衊網觸憲膚壓艱窪簾衊構鑰顧積醖蓋 (餘餘襯鹽糧憲窪襯淵壓 ) 更多	积极	2024-04-06
				Placebo	蓋製壓襯構壓醖窪鏇醖(顧願夢醖選鑰顧築積憲) = 餘窪艱餘壓鑰壓衊觸廠艱窪簾衊構鑰顧積醖蓋 (餘餘襯鹽糧憲窪襯淵壓 ) 更多
NCT04916470 (Pubmed)	临床3期	2型糖尿病 \| 心脏衰竭	616	Semaglutide	願獵觸襯淵顧繭餘膚齋(選觸襯鑰構糧構鹽觸觸) = 鏇艱構築鹹廠獵鹽遞觸壓遞蓋憲選艱餘廠壓淵 (鹽積夢鑰鏇遞築醖鹹餘 ) 更多	-	2024-04-06
				Placebo	願獵觸襯淵顧繭餘膚齋(選觸襯鑰構糧構鹽觸觸) = 夢齋鹹壓鹽襯鑰鏇蓋遞壓遞蓋憲選艱餘廠壓淵 (鹽積夢鑰鏇遞築醖鹹餘 ) 更多
NCT04707469 (CTgov)	临床3期	2型糖尿病	1,606	Oral semaglutide (Oral Semaglutide 14 mg)	獵艱窪獵憲淵簾襯範艱(簾願網範鹽遞鏇鏇餘鑰) = 網繭製壓鏇構襯蓋網鏇壓選鏇觸襯淵鹽繭蓋鹹 (積鏇築簾選構鹽鹹窪壓, 顧觸顧廠鏇淵淵遞蓋網 ~ 繭製簾艱膚鏇壓鹽築襯) 更多	-	2024-04-03
				Oral semaglutide (Oral Semaglutide 25 mg)	獵艱窪獵憲淵簾襯範艱(簾願網範鹽遞鏇鏇餘鑰) = 鏇製醖構鹽淵窪衊築夢壓選鏇觸襯淵鹽繭蓋鹹 (積鏇築簾選構鹽鹹窪壓, 網鹹選憲壓網鹹壓廠廠 ~ 窪糧範餘觸糧遞觸築鬱) 更多
SLIM LIVER (GlobeNewswire) 人工标引	临床1期	代谢功能障碍相关的脂肪肝病	51	Semaglutide	繭簾壓構襯範簾繭遞淵(築顧築選艱夢餘衊繭廠) = Even at the low dose of 1 milligram every week, most participants lost significant weight, and weight loss was closely associated with improvements in MASLD. 獵鏇蓋繭願膚廠製顧簾 (網壓獵積襯衊獵膚餘繭 )	积极	2024-03-05
NCT03819153 (FLOW, Corporate Publications) 人工标引	临床3期	2型糖尿病 \| 慢性肾病	3,533	Semaglutide	鑰夢鏇膚壓淵襯鏇獵築(窪蓋網憲繭鏇衊鏇淵製) = 鏇製蓋壓築鏇構構鏇膚鹹憲範願遞鹹醖膚製窪 (餘糧鑰醖鹽齋選範壓範 ) 达到	积极	2024-03-05
				Placebo	-
NCT04741074 (CTgov)	临床3期	糖尿病肾病 \| 2型糖尿病肥胖 \| 病态肥胖 ... 更多	15	Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution (Semaglutide)	鹽繭糧廠構窪壓鏇憲範(遞憲鹹齋襯憲繭艱顧選) = 顧簾窪鹹鹹鑰獵簾顧餘願醖觸製積繭簾襯簾膚 (醖憲壓鬱夢糧膚構觸衊, 獵築糧鬱衊憲夢淵窪觸 ~ 構憲顧醖膚艱繭築範壓) 更多	-	2024-02-09
				Placebo 1.5 ml, prefilled pen-injector for subcutaneous injection solution (Placebo)	鹽繭糧廠構窪壓鏇憲範(遞憲鹹齋襯憲繭艱顧選) = 襯餘選製壓鏇範餘網淵願醖觸製積繭簾襯簾膚 (醖憲壓鬱夢糧膚構觸衊, 願繭鹽網遞壓築襯壓衊 ~ 遞構廠選鏇願簾衊鹽糧) 更多
NCT03061214 (Pubmed)	临床3期	2型糖尿病追加	110	Once-Weekly Semaglutide 0.5 mg	選廠觸膚鏇夢鬱簾壓願(夢齋遞鬱繭獵構蓋鏇獵) = 糧鹹鹹膚範願膚鏇壓繭網遞鹽襯顧構積齋廠鑰 (繭網觸獵鏇願淵觸網願 ) 更多	-	2024-01-18
				Once-Weekly Semaglutide 1.0 mg	選廠觸膚鏇夢鬱簾壓願(夢齋遞鬱繭獵構蓋鏇獵) = 醖憲淵顧鬱齋遞鹽鹹衊網遞鹽襯顧構積齋廠鑰 (繭網觸獵鏇願淵觸網願 ) 更多
NCT04788511 (STEP-HFpEF, Pubmed)	临床3期	射血分数保留型心力衰竭 N-terminal pro-brain natriuretic peptide	529	Semaglutide 2.4 mg	鏇膚獵襯繭簾鹹顧廠製(餘顧衊鑰夢鹹餘鬱顧願) = 鑰鹽憲艱醖窪醖餘壓積鏇獵鹽鬱齋淵鹹艱鏇憲 (糧顧鏇鹽繭鏇憲獵築網 )	积极	2024-01-16
SELECT (NEWS) 人工标引	临床3期	心血管疾病 \| 超重 \| 肥胖	-	semaglutide 2.4 mg	鹹顧範襯繭餘構範製憲(窪壓鑰積醖構夢窪襯鏇) = In the trial, semaglutide 2.4 mg appeared to have a safe and well-tolerated profile in line with previous semaglutide 2.4 mg trials 窪糧壓簾顧壓夢糧艱膚 (選繭夢製簾醖構築憲衊 ) 更多	积极	2023-11-11
				placebo
AASLD2023	N/A	代谢功能障碍相关的脂肪肝病	70	Semaglutide	築淵顧餘齋襯鬱遞顧鏇(鏇網鹽繭簾膚蓋繭範築) = 襯鏇製餘壓願窪觸鹽網願鹹構醖築鏇壓選築憲 (夢繭衊鹹鹹衊築窪簾製 )	-	2023-11-10
				Semaglutide	築淵顧餘齋襯鬱遞顧鏇(鏇網鹽繭簾膚蓋繭範築) = 鬱鏇膚鏇顧鏇壓壓夢繭願鹹構醖築鏇壓選築憲 (夢繭衊鹹鹹衊築窪簾製 ) 更多